Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 1.00 |
| ▸ | CDK4 | P11802 | 8/20 | 1.00 |
| ▸ | EIF2AK2 | P19525 | 8/20 | 0.68 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203801 | 0.85 | CDK2 (0.74) | CDK2CDK4EIF2AK2SYKMEN1 | |
| SCHEMBL4615060 | 0.85 | CDK2 (1.00) | CDK2CDK4EIF2AK2SYKMEN1 | |
| SCHEMBL4613384 | 0.82 | CDK2 (1.00) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL27584438 | 0.81 | CDK2 (0.67) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL4615505 | 0.81 | CDK2 (0.67) | CDK2CDK4EIF2AK2SYKMEN1 | |
| SCHEMBL4614634 | 0.81 | CDK2 (1.00) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL4616002 | 0.81 | CDK2 (1.00) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL5204445 | 0.79 | CDK2 (0.65) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL5274096 | 0.78 | CDK2 (0.73) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL4614605 | 0.78 | CDK2 (0.63) | CDK2CDK4EIF2AK2SYKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572211-B1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | CYCLACEL LTD (GB) | 2008-02-20 | — | — | EP | claimed |
| US-7262202-B2 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-28 | — | — | US | claimed |
| US-20070185134-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| EP-1373253-B1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT | CYCLACEL LTD (GB) | 2007-06-20 | — | — | EP | claimed |
| US-20050282843-A1 | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | CYCLACEL LIMITED (GB) | 2005-12-22 | — | — | US | claimed |
| EP-1572211-A1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | Cyclacel Limited (GB) | 2005-09-14 | — | — | EP | claimed |
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | US | claimed |
| WO-2004056368-A1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | WO | claimed |
| EP-1572211-B1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | CYCLACEL LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1572211-B1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | CYCLACEL LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-7262202-B2 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
| US-20070185134-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20050282843-A1 | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | CYCLACEL LIMITED (GB) | 2005-12-22 | — | — | US | disclosed |
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | US | disclosed |
| WO-2004056368-A1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282843-A1 | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | HRH2, HRH3, CYTH3 | CDK2 810/4885CDK4 1254/4885EIF2AK2 629/4885 |
| US-20070185134-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CDK2, CCNK, CDK3 | CDK2 1/4885CDK4 5/4885EIF2AK2 831/4885 |
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CDK2, CCNK, CDK3 | CDK2 1/4885CDK4 5/4885EIF2AK2 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.